

Supplementary Table 1. Ajou-scoring system, comprising laboratory and clinical parameters for PAD

Point value (normal reference level)	0	1	2	3	4	5
Laboratory						
IgG1 (mg/dL) (382.4–928.6)	≥ 741	519–740		296–518		0–295
IgG2 (mg/dL) (241.8–700.3)	≥ 421	294–420		168.4–293		0–167
IgG3 (mg/dL) (21.8–176.1)	≥ 27	19–26		11–18		0–10
IgG4 (mg/dL) (3.9–86.4)	≥ 58	41–57		23–40		0–22
Total IgG (mg/dL) (700–1,600)	≥ 1,233	863–1232		493–862		0–492
Total IgA (mg/dL) (70–400)	≥ 239	167–238		96–166		0–95
Total IgM (mg/dL) (40–230)	≥ 150	101–149		61–100		0–60
Clinical history						
Recurrent viral infections (colds, herpes, warts, and condyloma) (within 1 yr)	None	1	2	3	4	> 5
Recurrent sinus infections in the absence of allergy (within 1 yr)	None	1	2	3	4	> 5
Recurrent need for intravenous antibiotics to clear infections (within 1 yr)	None	1	2	3	4	> 5 or Prophylactic
Recurrent pneumonia (within 1 yr)	None	1	2	3	4	> 5
New ear infections (within 1 yr)	None	1	2	3	4	> 5
Persistent stomatitis or fungal infection on skin or elsewhere	None			Present		
Chronic diarrhea with weight loss	None			Present		
Recurrent, deep abscesses of the skin or internal organs	None			Present		
Infection with normally harmless tuberculosis-like bacteria (NTM)	None			Present		
A family history of PAD	None			present		
Other						
Pulmonary function tests	Normal	FEV1/FVC < 80%		FEV1/FVC < 70%		FEV1/FVC < 60%
Bronchiectasis	None			Localized		Bilateral, cystic

PAD, primary antibody deficiency; Ig, immunoglobulin; IVIGRT, intravenous immunoglobulin replacement therapy; NTM, nontuberculous mycobacteria.

Point values reflect deviations from normal reference levels and clinical severity within 1 year.

Recurrent infection items were scored according to the number of episodes per year (0–5 points), with increasing scores reflecting higher frequency rather than a diagnostic threshold. Prophylactic therapy was scored in the highest category where applicable.